UBS O'Connor’s Orion Biotech Opportunities Corp. Class A Ordinary Share ORIA Stock Holding History

UBS O'Connor’s Portfolio ORIA Stock Details ORIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-235,390	Closed	-$2.41M	–	729
2023 Q1	$2.41M	Buy	+235,390	New	+$2.39M	0.06%	272
2022 Q4	–	Sell	-237,693	Closed	-$2.34M	–	660
2022 Q3	$2.34M	Sell	237,693 -23,795	-9%	-$233K	0.03%	566
2022 Q2	$2.55M	Buy	+261,488	New	+$2.55M	0.03%	584
2022 Q1	–	Sell	-256,880	Closed	-$2.51M	–	520
2021 Q4	$2.51M	Buy	256,880 +6,880	+3%	+$67.5K	0.02%	517
2021 Q3	$2.44M	Buy	+250,000	New	+$2.44M	0.02%	483

UBS O'Connor's ORIA Position: Q2 2023 in Review

UBS O'Connor sold out of Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) in Q2 2023, closing a stake of 235,390 shares — an estimated $2.41M sold.

UBS O'Connor first reported a position in ORIA in Q3 2021 and held it in 5 quarters. The position peaked at $2.55M in Q2 2022. 0 funds tracked by Wall St. Rank hold ORIA as of Q2 2023.

UBS O'Connor reported no remaining Orion Biotech Opportunities Corp. Class A Ordinary Share position as of Q2 2023 after selling out during the quarter.
UBS O'Connor sold 235,390 Orion Biotech Opportunities Corp. Class A Ordinary Share shares in Q2 2023, an estimated $2.41M.
UBS O'Connor first reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share in Q3 2021 and held it in 5 quarters.
UBS O'Connor's Orion Biotech Opportunities Corp. Class A Ordinary Share position peaked at $2.55M in Q2 2022.
0 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Class A Ordinary Share as of Q2 2023.

Based on UBS O'Connor's 13F filing for Q2 2023, filed 14 Aug 2023.